Anti-corporate activism

DSM provides Q1 2023 trading update

Retrieved on: 
Tuesday, May 2, 2023
Growth, DSM, Nutrition, 2012 Six-red World Championship, Vitamin A, Health, Beauty, Environment, APM, Continuous operation, Anti-corporate activism, Euronext Amsterdam, Fine chemical, Pharmaceutical industry

HEERLEN, Netherlands, May 2, 2023 /PRNewswire/ -- 

Key Points: 
  • 1 Continuing Operations reflects the results of DSM's Health, Nutrition & Bioscience and Corporate Activities as of 1 January 2022.
  • Organic sales growth is the total impact of volume and price/mix.
  • Looking to the future, we are very pleased at the overwhelmingly positive response to the exchange of DSM shares for DSM-Firmenich shares.
  • With the imminent completion of the merger, once DSM and Firmenich's activities have been consolidated and the combined business plan approved by the DSM-Firmenich Board, it is intended that DSM-Firmenich will provide an outlook for the remainder of 2023 at the publication of its Half Year results on 2 August 2023.

DSM reports 2022 results

Retrieved on: 
Thursday, February 16, 2023
Material, Anti-corporate activism, Woman, Euronext Amsterdam, Climate change, DSM, Firmenich, Electricity, Injury, Exchange offer, Foodservice, Enterprise value, Employee resource group, Sale, Engineering, World's oldest architectural practices continuously operating, CDP, Nutrition, Food, HNB, CET, 2012 Six-red World Championship, Science, APM, Beauty, Adjustment, Advent International, Safety, Climate, Growth, Mass meeting, Avient Corporation, LANXESS, Exchange, COVID-19, Initial exchange offering, Mental health, Bookkeeping, Renewable energy, Fine chemical, Pharmaceutical industry, Security (finance), Holding company, Offering circular, Health, List of life sciences

1 Continuing Operations reflects the results of DSM's Health, Nutrition & Bioscience and Corporate Activities as of 1 January 2022.

Key Points: 
  • 1 Continuing Operations reflects the results of DSM's Health, Nutrition & Bioscience and Corporate Activities as of 1 January 2022.
  • DSM became a Health, Nutrition & Bioscience ('HNB') company, organized, as of January 1, 2022, in three business groups: Animal Nutrition & Health; Health, Nutrition & Care; and Food & Beverage.
  • An interim dividend for the year 2022 of €0.93 per ordinary share was recognized as a liability in the second quarter of 2022.
  • Subject to the General Meeting of DSM-Firmenich resolving to pay this dividend, eligible DSM shareholders who tender their DSM ordinary shares for DSM-Firmenich ordinary shares will receive a total dividend of about €2.53 over 2022 (vs €2.50 over 2021).

DSM provides nine months 2022 trading update

Retrieved on: 
Tuesday, November 1, 2022
2009 Six-red World Grand Prix, Adjustment, Growth, DSM, Health, Anti-corporate activism, Nutrition, Continuous operation, Drink, Colloid, APM, Milk, Fine chemical

Animal Nutrition & Health volumes were in-line with a strong prior year that had delivered 14% volume growth.

Key Points: 
  • Animal Nutrition & Health volumes were in-line with a strong prior year that had delivered 14% volume growth.
  • DSM has lowered its full year 2022 outlook, and now expects its Adjusted EBITDA for Continuing Operations (Health, Nutrition & Bioscience and Corporate Activities) to increase by a low-single digits.
  • 1 Continuing Operations reflects the results of DSM's Health, Nutrition & Bioscience and Corporate Activities as of 1 January 2022.
  • Details on how to access this call can be found on the DSM website, www.dsm.com .

DSM reports H1 2022 results

Retrieved on: 
Tuesday, August 2, 2022
People, Income, Sale, Anti-corporate activism, Digital technology, Enterprise value, Targets, DSM, Advent International, Food, Female, History, Electricity, APM, Avient Corporation, Solution, Intention, Workforce, Engineering, Safety, COVID-19, Beauty, HNB, LANXESS, Acceleration, Nutrition, Goal, 2009 Six-red World Grand Prix, Growth, Science, Continuous operation, GHG, Public expenditure, EBITDA, Fine chemical, Renewable energy, Pharmaceutical industry, List of life sciences, Health

On April 20, 2022 DSM announced that it had reached an agreement to sell its Protective Materials business to Avient Corporation for an Enterprise Value of 1.44 billion.

Key Points: 
  • On April 20, 2022 DSM announced that it had reached an agreement to sell its Protective Materials business to Avient Corporation for an Enterprise Value of 1.44 billion.
  • On May 31, 2022 DSM announced that it had reached an agreement to sell its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of 3.85 billion.
  • DSM and Firmenich anticipate that the proposed combination will close in H1 2023.
  • During the first half of 2022 DSM made further progress on its path to reaching net-zero greenhouse gas emissions across its value chain by 2050.

HAGENS BERMAN Alerts Katapult Holdings (KPLT/FSRV) Investors to Investor Deadline in Securities Class Action, Encourages Investors with Losses to Contact Firm’s Attorneys Now

Retrieved on: 
Monday, September 6, 2021
Anti-corporate activism, Corporate finance, Private equity, Special-purpose acquisition company, Katapult, Whistleblower, KPLT, Steve Berman, Articles, Human rights, Finance

The truth emerged on Aug. 10, 2021, just two months after Katapult closed the merger and gave its 2021 financial guidance.

Key Points: 
  • The truth emerged on Aug. 10, 2021, just two months after Katapult closed the merger and gave its 2021 financial guidance.
  • Were focused on investors losses and proving Katapult misrepresented its growth potential before and after the SPAC merger, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Katapult Holdings or FinServe and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

HAGENS BERMAN Alerts Cassava Sciences, Inc. (SAVA) Investors to Securities Fraud Class Action, Encourages Investors with Losses to Contact Firm’s Attorneys Now

Retrieved on: 
Saturday, September 4, 2021
Agriculture, Food and drink, Articles, Staple foods, Tubers, Anti-corporate activism, Freedom of expression, Freedom of speech, Whistleblower, Cassava, Steve Berman

The petition raises serious concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate.

Key Points: 
  • The petition raises serious concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate.
  • Were focused on investors losses and proving Cassava manipulated clinical data for simufilam, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Cassava and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Zymergen Inc. (ZY) on Behalf of Investors

Retrieved on: 
Wednesday, August 4, 2021
Legal, Professional Services, Civil rights and liberties, Anti-corporate activism, Freedom of expression, Freedom of speech, Labour law, Whistleblower, Workplace bullying, Human rights, Articles

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Zymergen Inc. (Zymergen or the Company) (NASDAQ: ZY ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Zymergen Inc. (Zymergen or the Company) (NASDAQ: ZY ) investors concerning the Companys possible violations of the federal securities laws.
  • As a result, Zymergen no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.
  • Whistleblower Notice: Persons with non-public information regarding Zymergen should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Live Ventures Incorporated (LIVE) on Behalf of Investors

Retrieved on: 
Wednesday, August 4, 2021
Legal, Professional Services, Civil rights and liberties, Anti-corporate activism, Freedom of expression, Freedom of speech, Labour law, Whistleblower, Workplace bullying, Human rights, Articles

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Live Ventures Incorporated (Live Ventures or the Company) (NASDAQ: LIVE ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Live Ventures Incorporated (Live Ventures or the Company) (NASDAQ: LIVE ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, the Companys share price fell as much as 22% during afterhours trading on August 3, 2021, thereby injuring investors.
  • Whistleblower Notice: Persons with non-public information regarding Live Ventures should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Zymergen Inc. (ZY) on Behalf of Investors

Retrieved on: 
Wednesday, August 4, 2021
Legal, Professional services, Civil rights and liberties, Anti-corporate activism, Freedom of expression, Freedom of speech, Labour law, Whistleblower, Workplace bullying, Human rights, Articles

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zymergen Inc. (Zymergen or the Company) (NASDAQ: ZY ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zymergen Inc. (Zymergen or the Company) (NASDAQ: ZY ) investors concerning the Companys possible violations of the federal securities laws.
  • As a result, Zymergen no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.
  • Whistleblower Notice: Persons with non-public information regarding Zymergen should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

Retrieved on: 
Wednesday, August 4, 2021
Legal, Professional services, Civil rights and liberties, Anti-corporate activism, Freedom of expression, Freedom of speech, Labour law, Whistleblower, Workplace bullying, Human rights, Articles

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Annovis Bio, Inc. (Annovis or the Company) (NYSE: ANVS ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Annovis Bio, Inc. (Annovis or the Company) (NYSE: ANVS ) investors concerning the Companys possible violations of the federal securities laws.
  • On July 28, 2021, after the market closed, Annovis reported that Posiphen failed to show statistical significance in treating Alzheimer's and Parkinson's patients relative to a placebo.
  • Whistleblower Notice: Persons with non-public information regarding Annovis should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.